CY1115798T1 - Μεθοδος για τη διαγνωση καρκινων που εκφραζουν μια κολοβωμενη παραλλαγη του υποδοχεα her2 - Google Patents

Μεθοδος για τη διαγνωση καρκινων που εκφραζουν μια κολοβωμενη παραλλαγη του υποδοχεα her2

Info

Publication number
CY1115798T1
CY1115798T1 CY20141100995T CY141100995T CY1115798T1 CY 1115798 T1 CY1115798 T1 CY 1115798T1 CY 20141100995 T CY20141100995 T CY 20141100995T CY 141100995 T CY141100995 T CY 141100995T CY 1115798 T1 CY1115798 T1 CY 1115798T1
Authority
CY
Cyprus
Prior art keywords
her2 receptor
cancer
expressioning
diagnosis
reception
Prior art date
Application number
CY20141100995T
Other languages
English (en)
Inventor
López Joaquín Arribas
Kim Pedersen
Pier-Davide Angellini
Palau Josep Lluis Parra
Sirle Laos
Torres José Baselga
Original Assignee
Fundació Privada Institut De Recerca Hospital Universitari Vall Hebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundació Privada Institut De Recerca Hospital Universitari Vall Hebron filed Critical Fundació Privada Institut De Recerca Hospital Universitari Vall Hebron
Publication of CY1115798T1 publication Critical patent/CY1115798T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μια μέθοδο διάγνωσης και θεραπείας καρκίνων που εκφράζουν τον υποδοχέα HER2. Η εφεύρεση παρέχει αντισώματα ή θραύσματα αυτών που αναγνωρίζουν έναν επίτοπο μιας κολοβωμένης μορφής ενός υποδοχέα HER2, με τον εν λόγω επίτοπο να ορίζεται από μια αλληλουχία που περιλαμβάνεται στη SEQ ID ΝΟ:2. Η εφεύρεση παρέχει επίσης μια μέθοδο διάγνωσης καρκίνου, η οποία περιλαμβάνει την ανίχνευση της παρουσίας της κολοβωμένης μορφής του υποδοχέα HER2 που αποτελείται από την αλληλουχία αμινοξέων SEQ ID ΝΟ:1 σε δείγμα ασθενούς.
CY20141100995T 2008-06-02 2014-11-28 Μεθοδος για τη διαγνωση καρκινων που εκφραζουν μια κολοβωμενη παραλλαγη του υποδοχεα her2 CY1115798T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200801652A ES2342646B1 (es) 2008-06-02 2008-06-02 Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
EP09772265.6A EP2293819B1 (en) 2008-06-02 2009-06-05 Method for diagnosing cancers expressing a truncated her2 receptor variant

Publications (1)

Publication Number Publication Date
CY1115798T1 true CY1115798T1 (el) 2017-01-25

Family

ID=40911029

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100995T CY1115798T1 (el) 2008-06-02 2014-11-28 Μεθοδος για τη διαγνωση καρκινων που εκφραζουν μια κολοβωμενη παραλλαγη του υποδοχεα her2

Country Status (21)

Country Link
US (1) US8389227B2 (el)
EP (1) EP2293819B1 (el)
JP (2) JP5753079B2 (el)
KR (2) KR101785117B1 (el)
CN (1) CN102202692B (el)
AU (2) AU2009265921B2 (el)
BR (1) BRPI0914969A2 (el)
CA (1) CA2727365A1 (el)
CY (1) CY1115798T1 (el)
DK (1) DK2293819T3 (el)
EA (1) EA025218B1 (el)
ES (2) ES2342646B1 (el)
HK (1) HK1157658A1 (el)
HR (1) HRP20141158T1 (el)
IL (1) IL209769A (el)
MX (1) MX2010013419A (el)
PL (1) PL2293819T3 (el)
PT (1) PT2293819E (el)
SI (1) SI2293819T1 (el)
WO (1) WO2010000565A1 (el)
ZA (1) ZA201009010B (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638598B2 (en) * 2001-04-06 2009-12-29 The Trustees Of The University Of Pennsylvania ErbB interface peptidomimetics and methods of use thereof
EP2235536A4 (en) 2007-12-20 2011-05-04 Lab Corp America Holdings HER-2 DIAGNOSTIC METHODS
ES2342646B1 (es) * 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
US8349574B2 (en) 2009-01-15 2013-01-08 Laboratory Corporation Of America Holdings Methods of determining patient response by measurement of Her-3
CA2764386C (en) 2008-12-01 2018-05-01 Laboratory Corporation Of America Holdings P95-her2 antibodies and uses thereof
NZ596468A (en) * 2009-05-14 2013-11-29 Nestec Sa Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
EP2330131B1 (en) * 2009-12-07 2014-10-08 Fundació Privada Institució Catalana De Recerca I Estudis Avancats Antibodies against HER2 truncated variant CTF-611
CN103102414B (zh) * 2013-02-04 2014-08-27 无锡傲锐东源生物科技有限公司 抗her2蛋白单克隆抗体及其用途
RU2015150233A (ru) 2013-05-01 2017-06-02 Файв Прайм Терапьютикс, Инк. Способы лечения злокачественной опухоли
EP3825327A1 (en) 2014-03-11 2021-05-26 Molecular Templates, Inc. Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs
AU2015229583B2 (en) 2014-03-11 2020-07-09 Molecular Templates, Inc. Proteins comprising amino-terminal proximal Shiga toxin A Subunit effector regions and cell-targeting immunoglobulin-type binding regions
EP3660035A1 (en) 2015-05-30 2020-06-03 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
CA2991259A1 (en) 2015-07-26 2017-02-02 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
SG11201810032PA (en) 2016-05-12 2018-12-28 Agency Science Tech & Res Anti-erbb-2 antibodies and uses thereof
WO2018060301A1 (en) 2016-09-30 2018-04-05 F. Hoffmann-La Roche Ag Bispecific antibodies against cd3
US20200024312A1 (en) 2017-01-25 2020-01-23 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
MX2019009726A (es) 2018-04-17 2020-02-05 Molecular Templates Inc Moleculas con direccion hacia her2 que comprenden andamiajes de la sub-unidad a de la toxina shiga desinmunizados.
CN110172448B (zh) * 2019-05-30 2020-07-28 中南大学湘雅二医院 一种滑膜肉瘤细胞系hSS-005R及其子代细胞系
MX2022000922A (es) 2019-07-23 2022-05-03 Mnemo Therapeutics Celulas inmunes defectuosas para suv39h1.
CN110865184B (zh) * 2019-12-04 2023-04-07 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） Srsp蛋白和srsp抗原表位肽的应用及诊断和治疗肿瘤的产品
EP3915576A1 (en) 2020-05-28 2021-12-01 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Chimeric antigen receptors specific for p95her2 and uses thereof
WO2023126458A1 (en) 2021-12-28 2023-07-06 Mnemo Therapeutics Immune cells with inactivated suv39h1 and modified tcr
EP4253418A1 (en) 2022-03-29 2023-10-04 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Immune cells expressing chimeric antigen receptors and bispecific antibodies and uses thereof
EP4279085A1 (en) 2022-05-20 2023-11-22 Mnemo Therapeutics Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
AU3352495A (en) 1994-08-30 1996-03-22 Barbara Ann Spruce Agents for inducing apoptosis and applications of said agents in therapy
EP0920522B1 (en) * 1996-08-14 2003-10-29 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES A vector for polynucleotide vaccines
US7371376B1 (en) * 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
SI1187632T1 (sl) 1999-05-14 2009-04-30 Genentech Inc Zdravljenje z anti-ErbB2 protitelesi
TR200200472T2 (tr) * 1999-08-27 2002-06-21 Genentech, Inc. Anti-Erb B2 antikorları ile tedavi için dozajlar
WO2005011607A2 (en) * 2003-08-01 2005-02-10 Smithkline Beecham Corporation Treatment of cancers expressing p95 erbb2
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
ES2342646B1 (es) * 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
CA2764386C (en) * 2008-12-01 2018-05-01 Laboratory Corporation Of America Holdings P95-her2 antibodies and uses thereof

Also Published As

Publication number Publication date
WO2010000565A1 (en) 2010-01-07
EA201001874A1 (ru) 2011-08-30
DK2293819T3 (en) 2014-12-08
HRP20141158T1 (hr) 2015-02-13
AU2009265921B2 (en) 2015-04-02
EP2293819B1 (en) 2014-09-03
EP2293819A1 (en) 2011-03-16
PL2293819T3 (pl) 2015-04-30
ES2342646B1 (es) 2011-04-26
AU2009265921A1 (en) 2010-01-07
KR101785117B1 (ko) 2017-11-07
KR20110031187A (ko) 2011-03-24
MX2010013419A (es) 2011-08-15
US8389227B2 (en) 2013-03-05
JP2015214546A (ja) 2015-12-03
CN102202692A (zh) 2011-09-28
BRPI0914969A2 (pt) 2015-10-20
IL209769A (en) 2016-04-21
ES2342646A1 (es) 2010-07-09
AU2015202854A1 (en) 2015-06-18
CA2727365A1 (en) 2010-01-07
PT2293819E (pt) 2014-12-09
IL209769A0 (en) 2011-02-28
CN102202692B (zh) 2014-03-12
US20090311262A1 (en) 2009-12-17
ES2528132T3 (es) 2015-02-04
ZA201009010B (en) 2012-03-28
JP2011525175A (ja) 2011-09-15
EA025218B1 (ru) 2016-12-30
KR20160140974A (ko) 2016-12-07
SI2293819T1 (sl) 2015-01-30
HK1157658A1 (en) 2012-07-06
JP5753079B2 (ja) 2015-07-22

Similar Documents

Publication Publication Date Title
CY1115798T1 (el) Μεθοδος για τη διαγνωση καρκινων που εκφραζουν μια κολοβωμενη παραλλαγη του υποδοχεα her2
CY1115927T1 (el) Αντισωματα εναντιον της κολοβωμενης παραλλαγης ctf-611 του her2
CY1118845T1 (el) Πρωτεϊνες συνδεσης αντιγονου υποδοχεα α il-17
CY1120913T1 (el) Μονοκλωνικα αντισωματα εναντι προγαστρινης και η χρηση τους
CY1124435T1 (el) Νουκλεικα οξεα που κωδικοποιουν ανθρωπινα αντισωματα σε sialyl-lewis α
CY1120414T1 (el) Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
CY1120286T1 (el) Πρωτεϊνες δεσμευσης υποδοχεα προλακτινης και χρησεις αυτων
CY1119591T1 (el) Πρωτεϊνες ειδικης συνδεσης και χρησεις αυτων
CY1122092T1 (el) Ιατρικη χρηση ανθρωπινων αντισωματων υψηλης συγγενειας κατα του ανθρωπινου υποδοχεα il-4
CY1114719T1 (el) Ανταγωνιστικα ανθρωπινου light-ειδικα ανθρωπινα μονοκλωνικα αντισωματα
CY1122557T1 (el) Μορια αντι-gcc αντισωματος και χρηση αυτων στη δοκιμη για επιδεκτικοτητα σε θεραπεια στοχευμενη σε gcc
CY1115572T1 (el) Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου
NZ707116A (en) Ly75 as cancer therapeutic and diagnostic target
CY1116488T1 (el) Αντισωματα anti-προπερδινης
DK2097453T3 (da) Monoklonale antistoffer mod humant Anti-Müllerian Hormon type II receptor (AMHR-II)
CY1112631T1 (el) ΜΕΘΟΔΟΙ ΤΑΥΤΟΠΟΙΗΣΗΣ ΟΓΚΩΝ ΠΟΥ ΑΠΟΚΡΙΝΟΝΤΑΙ ΣΕ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ΕrbB2
CY1115076T1 (el) ΕΝΑ ANTΙ-PDGFRα ΑΝΤΙΣΩΜΑ ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΜΕΤΑΣΤΑΤΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΩΝ ΟΣΤΩΝ
CY1118200T1 (el) Πολυπεπτιδια, πολυνουκλεοτιδια και συνθεσεις για χρηση στη θεραπεια λανθανουσας φυματιωσης
UA109633C2 (uk) Антитіло людини проти тканинного фактора
FR2933773B1 (fr) Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
AR084210A1 (es) PROTEINAS DE UNION AL TNF-a
UA114108C2 (uk) Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
CL2007003649A1 (es) Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70.
BR112012003064B8 (pt) anticorpo ou fragmento de ligação de antígeno do mesmo, combinação que os compreende, método de detecção de infecção por rsv, moléculas de ácido nucléico, e método de produção de um anticorpo ou fragmento de ligação de antígeno do mesmo
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения